JPH05506427A - 糖尿病治療に有用なglp―1アナログ - Google Patents
糖尿病治療に有用なglp―1アナログInfo
- Publication number
- JPH05506427A JPH05506427A JP91503618A JP50361891A JPH05506427A JP H05506427 A JPH05506427 A JP H05506427A JP 91503618 A JP91503618 A JP 91503618A JP 50361891 A JP50361891 A JP 50361891A JP H05506427 A JPH05506427 A JP H05506427A
- Authority
- JP
- Japan
- Prior art keywords
- glp
- amino acid
- peptide
- paragraph
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (14)
- 1.II型糖尿病の治療薬として有用なペプチドであって、該ペプチドが、島細 胞からのインシュリンの放出を刺激するのに、グルカゴンよりも強力であり、該 ペプチドが、実質的に、GLP−1(7−34)、GLP−1(7−35)、G LP−1(7−36)またはGLP−1(7−37)あるいはそのC末端アミド 形態からなり、以下よりなる群から選択される少なくとも1つの改変を有する、 ペプチド。 (a)26位および/または34位のリシンを、中性アミノ酸、アルギニンまた はD形リシンに置換、および/または36位のアルギニンを、中性アミノ酸、リ シンまたはD形アルギニンに置換; (b)31位のトリプトファンを、酸化耐性アミノ酸に置換(c)以下の少なく とも1つの置換: 16位のVをYに; 18位のSをKに; 21位のEをDに; 22位のGをSに; 23位のQをRに; 24位のAをRに;および 26位のKをQに; (d)以下の少なくとも1つを含む置換:8位のAを、他の小中性アミノ酸に; 9位のEを、他の酸性アミノ酸または中性アミノ酸に10位のGを、他の中性ア ミノ酸に;および15位のDを、他の酸性アミノ酸に;ならびに(e)7位のヒ スチジンを、他の中性アミノ酸、あるいはDまたはNアシル化またはアルキル化 形のヒスチジンに置換、ここで、(a)、(b)、(d)および(e)において 、置換するアミノ酸は、必要に応じて、D形であり得、そして7位に置換するア ミノ酸は、必要に応じて、Nアシル化またはNアルキル化形であり得る。
- 2.唯一の改変が、請求項1のパラグラフ(a)に記載されるものであり、26 位および/または34位のリシンを置換するアミノ酸が、K+、G、S、A、L 、I、Q、M、RおよびR+からなる群から選択され、そして36位のアルギニ ンを置換するアミノ酸が、K、K+、G、S、A、L、I、Q、MおよびR+か らなる群から選択され、 必要に応じて、請求項1のもう1つの別のパラグラフに記載の改変と組合わされ る、請求項1に記載のペプチド。
- 3.唯一の改変が、請求項1のパラグラフ(b)に記載されるものであり、そし て31位のトリプトファンを置換するアミノ酸が、F、V、L、I、AおよびY からなる群から選択され、必要に応じて、請求項1のもう1つの別のパラグラフ に記載の改変と組合わさる、請求項1に記載のペプチド。
- 4.唯一の改変が、請求項1のパラグラフ(c)に記載されるものであり、22 位のGをSに置換すること、23位および24位のそれぞれQおよびAをRに置 換すること、ならびに26位のKをQに置換することを組合せて行ったが、ある いは16位のVをYで置換すること、および18位のSをKで置換することを行 ったが、あるいはこれらの置換と21位のEをDで置換することを行っており、 必要に応じて、請求項1のもう1つの別のパラグラフに記載の改変と組合わされ る、請求項1に記載のペプチド。
- 5.唯一の改変が、請求項1のパラグラフ(d)に記載されるものであり、8位 のアラニンを置換する小さい中性アミノ酸が、S、S+、G、C、C+、Sar 、A+、beta−alaおよびAibからなる群から選択され、そして9位の グルタミン酸を置換する酸性または中性アミノ酸1が、E+、D、D+、Cya 、T、T+、N、N+、Q、Q+、Cit、MSOおよびアセチル−Kからなる 群から選択され、そして10位のグリシンを置換する代替の中性アミノ酸が、S 、S+、Y、Y+、T、T+、N、N+、Q、Q+、Cit、MSO、アセチル −K、FおよびF+からなる群から選択され、 必要に応じて、請求項1のもう1つの別のパラグラフに記載の改変と組合わされ る、請求項1に記載のペプチド。
- 6.唯一の改変が、請求項1のパラグラフ(e)に記載されるものであり、7位 のヒスチジンを置換するアミノ酸が、H+、Y、Yt、F、F+、R、Rt、O rn、Orn+、M、M+、N−ホルミル−H、N−ホルミル−H+、N−アセ チル−H、N−アセチル−H+、N−イソプロビル−H、N−イソプロピル−H +、N−アセチル−K、H−アセチル−K+、PおよびP+からなる群から選択 され、必要に応じて、請求項1のもう1つの別のパラグラフに記載の改変と組合 わされる、請求項1に記載のペプチド。
- 7.以下からなる群から選択される、請求項1に記載のペプチド: (H+)7−GLP−1(7−37) (Y)7−GLP−1(7−37) (N−アセチル−H)7−GLP−1(7−37)(N−イソプロピル−H)7 −GLP−1(7−37)(A+)6−GLP−1(7−37) (E+)9−GLP−(7−37) (D)9−GLP−1(7−37) (D+)9−GLP−1(7−37) (F+)10−GLP−1(7−37)(S)22(R)23(R)24(Q) 26−GLP−1(7−37)、および(S)8(Q)9(Y)16(K)18 (D)21−GLP−1(7−37)。
- 8.II型糖尿病の治療薬として有用なペプチドであって、該ペプチドが、GL P−1(7−37)と比較して、プラズマ中での分解耐性が向上しており、該ペ プテドが、実質的に、GLP−(7−34)、GLP−1(7−35)、GLP −1(7−36)またはGLP−1(7−37)、あるいはそのC末端アミド形 からなり、以下からなる群から選択される少なくとも1つの改変を存する、ペプ チド:(a)7位のヒスチジンを、D形中性または酸性アミノ酸、あるいはD形 ヒスチジンに置換; (b)8位のアラニンを、D形アミノ酸に置換;および(c)7位のヒスチジン を、Nアシル化(1−6C)またはNアルキル化(1−6C)形態の代替アミノ 酸またはヒスチジンに置換。
- 9.唯一の改変が、請求項8のパラグラフ(a)に記載されるものであり、7位 のヒスチジンを置換するD形アミノ酸が、P+、D+、E+、N、Q+、L+、 V+、I+およびH+からなる群から選択され、 必要に応じて、請求項8のもう1つの別のパラグラフに記載の改変と組合わされ る、請求項8に記載のペプチド。
- 10.唯一の改変が、請求項8のパラグラフ(b)に記載されるものであり、8 位のD形アミノ酸が、P+、V+、L+、I+およびA+からなる群から選択さ れ、 必要に応じて、請求項8のもう1つの別のパラグラフに記載の改変と組合わされ る、請求項8に記載のペプチド。
- 11.唯一の改変が、請求項8のパラグラフ(c)に記載されるものであり、ア ルキル化またはアセチル化アミノ酸が、P、D、E、N、Q、V、L、I、Kお よびHからなる群から選択され、必要に応じて、請求項8のもう1つの別のパラ グラフに記載の改変と組合わされる、請求項8に記載のペプチド。
- 12.II型糖尿病の治療に有用な薬学組成物であって、薬学的に許容可能な賦 形剤と混合された形の、請求項1または8に記載の有効量のペプチドを含む、組 成物。
- 13.II型糖尿病の治療方法であって、このような治療を必要とする被検体に 、請求項1または8に記載のペプチドまたはその薬学組成物を有効量投与するこ とを包含する、方法。
- 14.以下からなる群から選択される、請求項8に記載のペプチド: (H+)7−GLP−1(7−37)、(N−アセチル−H)7−GLP−1( 7−37)、(N−イソプロピル−H)7−GLP−1(7−37)、(N−ア セチル−K)7−GLP−1(7−37)、および(A+)8−GLP−1(7 −37)。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46873690A | 1990-01-24 | 1990-01-24 | |
US468,736 | 1990-01-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000311202A Division JP2001151798A (ja) | 1990-01-24 | 2000-10-11 | 糖尿病治療に有用なglp−1アナログ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05506427A true JPH05506427A (ja) | 1993-09-22 |
JP3262329B2 JP3262329B2 (ja) | 2002-03-04 |
Family
ID=23861028
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50361891A Expired - Lifetime JP3262329B2 (ja) | 1990-01-24 | 1991-01-24 | 糖尿病治療に有用なglp―1アナログ |
JP2000311202A Pending JP2001151798A (ja) | 1990-01-24 | 2000-10-11 | 糖尿病治療に有用なglp−1アナログ |
JP2002315982A Pending JP2003192698A (ja) | 1990-01-24 | 2002-10-30 | 糖尿病治療に有用なglp−1アナログ |
JP2004081117A Pending JP2004196825A (ja) | 1990-01-24 | 2004-03-19 | 糖尿病治療に有用なglp−1アナログ |
JP2005022265A Pending JP2005132848A (ja) | 1990-01-24 | 2005-01-28 | 糖尿病治療に有用なglp−1アナログ |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000311202A Pending JP2001151798A (ja) | 1990-01-24 | 2000-10-11 | 糖尿病治療に有用なglp−1アナログ |
JP2002315982A Pending JP2003192698A (ja) | 1990-01-24 | 2002-10-30 | 糖尿病治療に有用なglp−1アナログ |
JP2004081117A Pending JP2004196825A (ja) | 1990-01-24 | 2004-03-19 | 糖尿病治療に有用なglp−1アナログ |
JP2005022265A Pending JP2005132848A (ja) | 1990-01-24 | 2005-01-28 | 糖尿病治療に有用なglp−1アナログ |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0512042B1 (ja) |
JP (5) | JP3262329B2 (ja) |
AT (1) | ATE164852T1 (ja) |
CA (1) | CA2073856C (ja) |
DE (1) | DE69129226T2 (ja) |
DK (1) | DK0512042T3 (ja) |
ES (1) | ES2113879T3 (ja) |
WO (1) | WO1991011457A1 (ja) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003502364A (ja) * | 1999-06-19 | 2003-01-21 | ノベックス・コーポレイション | 加水分解型親油性成分を有する両親媒性薬物−オリゴマー結合体およびその製造法および使用法 |
JP2003514532A (ja) * | 1999-11-19 | 2003-04-22 | トランスカーヨティック セラピーズ インコーポレイテッド | 生成物の産生量を最適化するための核酸構築体 |
WO2004087910A1 (ja) * | 2003-03-28 | 2004-10-14 | National Institute Of Agrobiological Sciences | 組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質 |
JP2005132845A (ja) * | 1998-12-07 | 2005-05-26 | Soc De Conseils De Recherches & D'applications Scientifiques Sas | Glp−1の類似体 |
WO2006126673A1 (ja) * | 2005-05-27 | 2006-11-30 | Daiichi Sankyo Company, Limited | 組み合わせによる糖尿病治療薬 |
JP2006342172A (ja) * | 1995-04-14 | 2006-12-21 | 1149336 オンタリオ インコーポレーテッド | グルカゴン様ペプチド−2、ならびにその治療への使用 |
JP2010538049A (ja) * | 2007-09-05 | 2010-12-09 | ノボ・ノルデイスク・エー/エス | 切断型glp−1誘導体及びその治療的使用 |
JP4732590B2 (ja) * | 1999-03-15 | 2011-07-27 | ノボ ノルディスク アクティーゼルスカブ | Glp−1及び近縁ペプチドのイオン交換クロマトグラフィー分離 |
JP2012511586A (ja) * | 2008-12-10 | 2012-05-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 医薬組成物 |
US8410047B2 (en) | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
JP2013514323A (ja) * | 2009-12-16 | 2013-04-25 | ノヴォ ノルディスク アー/エス | Glp−1アナログ及び誘導体 |
JP2014530892A (ja) * | 2011-10-28 | 2014-11-20 | ファリス バイオテック ゲーエムベーハー | 心臓虚血再灌流障害からの保護のためのポリペプチド |
US8895694B2 (en) | 2007-09-05 | 2014-11-25 | Novo Nordisk A/S | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use |
US9486504B2 (en) | 2003-12-09 | 2016-11-08 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US10960052B2 (en) | 2010-12-16 | 2021-03-30 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
US11033499B2 (en) | 2012-06-20 | 2021-06-15 | Novo Nordisk A/S | Tablet formulation comprising a GLP-1 peptide and a delivery agent |
US11034746B2 (en) | 2011-04-12 | 2021-06-15 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
US11123296B2 (en) | 2012-03-22 | 2021-09-21 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
US11833248B2 (en) | 2018-02-02 | 2023-12-05 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Families Citing this family (210)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
DK36492D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
USRE37302E1 (en) * | 1992-03-19 | 2001-07-31 | Novo Nordisk A/S | Peptide |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
EP0646128A1 (en) * | 1992-06-15 | 1995-04-05 | Scios Inc. | Glucagon-like peptide and insulinotropin derivatives |
HU225496B1 (en) * | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
EP0658568A1 (en) * | 1993-12-09 | 1995-06-21 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
DK144093D0 (ja) * | 1993-12-23 | 1993-12-23 | Novo Nordisk As | |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
AU5685296A (en) * | 1995-05-17 | 1996-11-29 | Novo Nordisk A/S | Immunoassay for glucagon like protein 1 (glp-1) in plasma |
US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
EP1566180A3 (en) * | 1996-08-30 | 2007-08-08 | Eli Lilly & Company | Use of GLP-1 or Analogs in Treatment of Myocardial Infarction |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
JP3149958B2 (ja) * | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
JP2000517308A (ja) * | 1996-08-30 | 2000-12-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―2誘導体 |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
ES2247676T3 (es) | 1997-01-07 | 2006-03-01 | Amylin Pharmaceuticals, Inc. | Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia. |
CA2283834A1 (en) * | 1997-03-31 | 1998-10-08 | James Arthur Hoffmann | Glucagon-like peptide-1 analogs |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
WO1999014239A1 (de) * | 1997-09-12 | 1999-03-25 | Wolf Georg Forssmann | Zusammensetzung zur therapie von diabetes mellitus und fettsucht |
DE69838916T2 (de) | 1997-11-14 | 2008-12-18 | Amylin Pharmaceuticals, Inc., San Diego | Neuartige exendin agonisten |
US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
EP1049486A4 (en) * | 1997-12-05 | 2006-01-04 | Lilly Co Eli | GLP-1 FORMULATIONS |
CA2319195A1 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
WO1999043707A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
ATE265224T1 (de) * | 1998-02-27 | 2004-05-15 | Novo Nordisk As | Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden |
FR2777283B1 (fr) * | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JPH11328947A (ja) | 1998-05-18 | 1999-11-30 | Nec Corp | 大規模fifo回路 |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
EP1306091A3 (en) | 1998-07-31 | 2003-05-21 | Novo Nordisk A/S | Stimulation of beta cell proliferation |
EP1666054A1 (en) | 1998-08-28 | 2006-06-07 | Eli Lilly & Company | Method for administering insulinotropic peptides |
CA2343268A1 (en) | 1998-09-17 | 2000-03-23 | Eli Lilly And Company | Protein formulations |
US6461834B1 (en) | 1998-11-06 | 2002-10-08 | Bionebraska, Inc. | Clostripain catalyzed amidation of peptides |
CN1935839B (zh) * | 1998-12-07 | 2012-06-06 | 益普生制药股份有限公司 | 胰高血糖素样肽-1的类似物 |
DK1137666T5 (da) * | 1998-12-07 | 2009-10-05 | Univ Tulane | GLP-1-analoger |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
SI1140148T1 (sl) | 1998-12-22 | 2006-04-30 | Lilly Co Eli | Stabilna formulacija raztopine glukagonu podobnega peptida-1 |
US6927214B1 (en) | 1999-01-15 | 2005-08-09 | Novo Nordisk A/S | Non-peptide GLP-1 agonists |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
US6444788B1 (en) | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
US6451974B1 (en) | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
CA2501421A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting exendin-4 |
DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
DE122008000018I1 (de) | 2000-01-21 | 2008-08-14 | Novartis Pharma Ag | Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica |
ES2253353T3 (es) | 2000-03-08 | 2006-06-01 | Novo Nordisk A/S | Reduccion del colesterol serico. |
EP1695983B1 (en) | 2000-06-16 | 2009-03-04 | Eli Lilly & Company | Glucagon-like peptide-1 analogs |
PE20020617A1 (es) | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
EP1970072A1 (en) | 2000-09-18 | 2008-09-17 | Sanos Bioscience A/S | Use of GLP-2 peptides for the treatment of hyperparathyroidism |
US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
CA2430934C (en) | 2000-12-01 | 2011-06-21 | Takeda Chemical Industries, Ltd. | A method of producing sustained-release preparations of a bioactive substance using high-pressure gas |
EP1351984A2 (en) | 2000-12-13 | 2003-10-15 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
CN1162446C (zh) | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
JP4227894B2 (ja) | 2001-08-23 | 2009-02-18 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド1アナログ |
US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
AR036711A1 (es) * | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
RU2332229C2 (ru) | 2002-02-20 | 2008-08-27 | Эмисфире Текнолоджис Инк. | Способ введения молекул glp-1 |
EA007434B1 (ru) | 2002-02-28 | 2006-10-27 | Прозидион Лимитед | Ингибиторы dpiv на основе глутаминила |
ATE432289T1 (de) | 2002-07-04 | 2009-06-15 | Zealand Pharma As | Glp-1 und behandlungsmethode für diabetes |
AU2003273300A1 (en) * | 2002-09-06 | 2004-03-29 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
AU2003271452A1 (en) | 2002-09-25 | 2004-04-19 | Theratechnologies Inc. | Modified glp-1 peptides with increased biological potency |
US7273921B2 (en) | 2002-09-25 | 2007-09-25 | Novo Nordisk A/S | Method for producing acylated peptides |
US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
KR20060009902A (ko) | 2003-05-05 | 2006-02-01 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (de) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
KR20060106812A (ko) | 2003-08-21 | 2006-10-12 | 노보 노르디스크 에이/에스 | 라세미화 아미노산을 포함하는 폴리펩티드의 분리 |
BRPI0414539B8 (pt) | 2003-09-19 | 2021-05-25 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
KR20120007079A (ko) | 2003-10-15 | 2012-01-19 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도 |
CN102784386A (zh) | 2003-11-20 | 2012-11-21 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
JP2007514752A (ja) * | 2003-12-16 | 2007-06-07 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Glp−1医薬組成物 |
WO2005058955A1 (en) | 2003-12-16 | 2005-06-30 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogues of glp-1 |
BRPI0417717A (pt) | 2003-12-18 | 2007-04-03 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
AU2005203925A1 (en) * | 2004-01-08 | 2005-07-21 | Theratechnologies Inc. | Glucagon-Like Peptide-1 analogs with long duration of action |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
EP2422807A3 (en) | 2004-02-11 | 2012-05-30 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
BRPI0512396A (pt) * | 2004-07-21 | 2008-03-11 | Ambrx Inc | polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente |
CN101128487B (zh) | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
SG159551A1 (en) | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
CA2596926A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Extended glp-1 compounds |
DK1888103T3 (da) | 2005-04-11 | 2012-04-23 | Amylin Pharmaceuticals Inc | Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
MY147393A (en) | 2005-09-14 | 2012-11-30 | Takeda Pharmaceutical | Administration of dipeptidyl peptidase inhibitors |
CA2622608C (en) | 2005-09-14 | 2014-08-19 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
DK1767545T3 (da) | 2005-09-22 | 2010-03-15 | Biocompatibles Uk Ltd | GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens |
WO2007051987A1 (en) * | 2005-11-01 | 2007-05-10 | Activotec Spp Limited | Insulinotropic compounds and uses thereof |
ES2572952T3 (es) | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
CN100374462C (zh) * | 2005-11-21 | 2008-03-12 | 大连帝恩生物工程有限公司 | 截短胰高血糖素样肽1(sGLP-1)、制法及其应用 |
US20100016547A1 (en) * | 2005-11-30 | 2010-01-21 | Takaomi Ito | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient |
ES2390286T3 (es) | 2005-12-16 | 2012-11-08 | Nektar Therapeutics | Conjugados poliméricos de GLP-1 |
MX2008013304A (es) | 2006-04-20 | 2008-10-27 | Amgen Inc | Compuestos de peptido 1 tipo glucagon. |
US20090074734A1 (en) * | 2006-05-02 | 2009-03-19 | Actogenix N.V. | Microbial intestinal delivery of obesity related peptides |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
MX2010004298A (es) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
CN102046207B (zh) | 2008-03-31 | 2013-08-28 | 葛兰素集团有限公司 | 药物融合物和缀合物 |
PE20100255A1 (es) | 2008-06-17 | 2010-04-25 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
WO2010015668A1 (en) | 2008-08-06 | 2010-02-11 | Novo Nordisk A/S | Conjugated proteins with prolonged in vivo efficacy |
ES2614427T3 (es) | 2008-11-07 | 2017-05-31 | The General Hospital Corporation | Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1) |
JP5756407B2 (ja) | 2008-12-08 | 2015-07-29 | ノヴォ ノルディスク アー/エス | ポリペプチドの向流精製 |
BRPI0922969A2 (pt) * | 2008-12-19 | 2019-09-24 | Univ Indiana Res & Tech Corp | pró-farmaco de amida baseado na superfamília de glucagon peptídeo. |
AU2010207725B2 (en) | 2009-01-22 | 2015-06-11 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
US8779103B2 (en) | 2009-03-27 | 2014-07-15 | Glaxo Group Limited | Drug fusions and conjugates |
BRPI1010600A2 (pt) | 2009-05-15 | 2016-03-15 | Novartis Ag | aril piridina como inibidores de aldosterona sintase |
AU2010247391A1 (en) | 2009-05-15 | 2011-12-01 | Novartis Ag | Benzoxazolone derivatives as aldosterone synthase inhibitors |
MA33364B1 (fr) | 2009-05-28 | 2012-06-01 | Novartis Ag | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine |
EA019511B1 (ru) | 2009-05-28 | 2014-04-30 | Новартис Аг | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина |
IN2012DN00377A (ja) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
AU2010303112A1 (en) | 2009-09-30 | 2012-04-26 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
EP2993169B1 (en) | 2009-11-17 | 2017-12-20 | Novartis AG | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
EP2507234B1 (en) | 2009-11-30 | 2014-03-12 | Novartis AG | Imidazole derivatives as aldosterone synthase inhibitors |
AU2011208625C1 (en) | 2010-01-22 | 2022-08-18 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
CA2787895A1 (en) | 2010-01-22 | 2011-07-28 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
CN102834393B (zh) | 2010-02-03 | 2015-07-22 | 武田药品工业株式会社 | 细胞凋亡信号调节激酶1抑制剂 |
WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
WO2011133948A2 (en) | 2010-04-22 | 2011-10-27 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
CA2797133C (en) | 2010-04-27 | 2019-08-06 | Zealand Pharma A/S | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
WO2011136361A1 (ja) | 2010-04-30 | 2011-11-03 | 株式会社 三和化学研究所 | 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質 |
WO2011143788A1 (en) | 2010-05-17 | 2011-11-24 | Zhejiang Beta Pharma Inc. | Novel glucagon like peptide analogs, composition, and method of use |
RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | アミド系インスリンプロドラッグ |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
WO2012061466A2 (en) | 2010-11-02 | 2012-05-10 | The General Hospital Corporation | Methods for treating steatotic disease |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
EP2685257A4 (en) | 2011-03-08 | 2014-10-01 | Sanwa Kagaku Kenkyusho Co | METHOD OF ANALYSIS |
WO2012136792A2 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Cck compositions |
WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
DK2723367T3 (en) | 2011-06-22 | 2017-07-17 | Univ Indiana Res & Tech Corp | Glucagon / GLP-1 receptor-CO-AGONISTS |
EP2729493B1 (en) | 2011-07-04 | 2020-06-10 | IP2IPO Innovations Limited | Novel compounds and their effects on feeding behaviour |
WO2013006692A2 (en) | 2011-07-06 | 2013-01-10 | The General Hospital Corporation | Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) |
MX2014005351A (es) | 2011-11-03 | 2014-05-28 | Zealand Pharma As | Conjugados de gastrina peptidicos de agonistas de receptor glp-1. |
US20150038417A1 (en) * | 2011-12-09 | 2015-02-05 | Novo Nordisk A/S | GLP-1 Agonists |
IN2014DN09297A (ja) | 2012-05-16 | 2015-07-10 | Glaxo Group Ltd | |
TWI599575B (zh) | 2012-06-21 | 2017-09-21 | 印第安納大學科技研究公司 | 表現gip受體活性之胰高血糖素類似物 |
EP2873422A4 (en) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
MX356957B (es) | 2012-07-23 | 2018-06-20 | Zealand Pharma As | Analogos del glucagon. |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
SI2956464T1 (en) | 2013-02-14 | 2018-08-31 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases) |
WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
CA2909045C (en) | 2013-05-02 | 2022-12-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
SG11201600211XA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
UY35671A (es) | 2013-07-25 | 2015-02-27 | Novartis Ag | Bioconjugados de polipéptidos de apelina sintética |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
MX368436B (es) | 2013-10-17 | 2019-10-03 | Zealand Pharma As | Analogos de glucagon acilados. |
EP3065767B1 (en) | 2013-11-06 | 2020-12-30 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
WO2015067716A1 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
AU2015340586B2 (en) | 2014-10-29 | 2020-04-30 | Zealand Pharma A/S | GIP agonist compounds and methods |
MA41580A (fr) | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
BR112017022009A2 (pt) | 2015-04-16 | 2018-07-03 | Zealand Pharma A/S | ?composto, método de produção e síntese do mesmo e seu uso, composição e conjunto terapêutico? |
WO2017210100A1 (en) * | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Glucagon-like peptide-1-t3 conjugates |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
BR112019010624A2 (pt) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | agonistas duplos de glp-1/glp-2 acilados e composição |
KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
CN115109166A (zh) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
JP2022507958A (ja) | 2018-11-27 | 2022-01-18 | ノバルティス アーゲー | 代謝障害の治療用のプロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)阻害薬としての環状四量体化合物 |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
EP3887388A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
GB201917723D0 (en) | 2019-12-04 | 2020-01-15 | Nv Rose Llc | Stable liquid formulations of glucagon-like peptide 1 or analogues thereof |
US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
EP4222176A4 (en) | 2020-09-30 | 2024-02-28 | Beijing QL Biopharmaceutical Co., Ltd. | POLYPEPTIDE CONJUGATES AND METHODS OF USE |
TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
CN114958883B (zh) * | 2022-04-12 | 2023-01-31 | 北京惠之衡生物科技有限公司 | 一种表达glp-1类似物的重组工程菌及其构建方法 |
WO2024106505A1 (ja) * | 2022-11-16 | 2024-05-23 | 株式会社ポル・メド・テック | 豚臓器又はその由来物を含む移植材の製造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1498425A1 (en) * | 1986-05-05 | 2005-01-19 | The General Hospital Corporation | Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions |
-
1991
- 1991-01-24 WO PCT/US1991/000500 patent/WO1991011457A1/en active IP Right Grant
- 1991-01-24 DK DK91903738.2T patent/DK0512042T3/da active
- 1991-01-24 CA CA002073856A patent/CA2073856C/en not_active Expired - Lifetime
- 1991-01-24 ES ES91903738T patent/ES2113879T3/es not_active Expired - Lifetime
- 1991-01-24 DE DE69129226T patent/DE69129226T2/de not_active Expired - Lifetime
- 1991-01-24 EP EP91903738A patent/EP0512042B1/en not_active Expired - Lifetime
- 1991-01-24 AT AT91903738T patent/ATE164852T1/de not_active IP Right Cessation
- 1991-01-24 JP JP50361891A patent/JP3262329B2/ja not_active Expired - Lifetime
-
2000
- 2000-10-11 JP JP2000311202A patent/JP2001151798A/ja active Pending
-
2002
- 2002-10-30 JP JP2002315982A patent/JP2003192698A/ja active Pending
-
2004
- 2004-03-19 JP JP2004081117A patent/JP2004196825A/ja active Pending
-
2005
- 2005-01-28 JP JP2005022265A patent/JP2005132848A/ja active Pending
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006342172A (ja) * | 1995-04-14 | 2006-12-21 | 1149336 オンタリオ インコーポレーテッド | グルカゴン様ペプチド−2、ならびにその治療への使用 |
JP4496183B2 (ja) * | 1995-04-14 | 2010-07-07 | 1149336 オンタリオ インコーポレーテッド | グルカゴン様ペプチド−2、ならびにその治療への使用 |
JP2010159259A (ja) * | 1995-04-14 | 2010-07-22 | 1149336 オンタリオ インコーポレーテッド | グルカゴン様ペプチド−2、ならびにその治療への使用 |
JP2005132845A (ja) * | 1998-12-07 | 2005-05-26 | Soc De Conseils De Recherches & D'applications Scientifiques Sas | Glp−1の類似体 |
JP2008001710A (ja) * | 1998-12-07 | 2008-01-10 | Soc De Conseils De Recherches & D'applications Scientifiques Sas | Glp−1の類似体 |
JP4620444B2 (ja) * | 1998-12-07 | 2011-01-26 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | Glp−1の類似体 |
JP4732590B2 (ja) * | 1999-03-15 | 2011-07-27 | ノボ ノルディスク アクティーゼルスカブ | Glp−1及び近縁ペプチドのイオン交換クロマトグラフィー分離 |
JP2003502364A (ja) * | 1999-06-19 | 2003-01-21 | ノベックス・コーポレイション | 加水分解型親油性成分を有する両親媒性薬物−オリゴマー結合体およびその製造法および使用法 |
JP2003514532A (ja) * | 1999-11-19 | 2003-04-22 | トランスカーヨティック セラピーズ インコーポレイテッド | 生成物の産生量を最適化するための核酸構築体 |
WO2004087910A1 (ja) * | 2003-03-28 | 2004-10-14 | National Institute Of Agrobiological Sciences | 組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質 |
US9486504B2 (en) | 2003-12-09 | 2016-11-08 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
US8410047B2 (en) | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
WO2006126673A1 (ja) * | 2005-05-27 | 2006-11-30 | Daiichi Sankyo Company, Limited | 組み合わせによる糖尿病治療薬 |
JP2010538049A (ja) * | 2007-09-05 | 2010-12-09 | ノボ・ノルデイスク・エー/エス | 切断型glp−1誘導体及びその治療的使用 |
US9657079B2 (en) | 2007-09-05 | 2017-05-23 | Novo Nordisk A/S | Truncated GLP-1 derivatives and their therapeutical use |
US8895694B2 (en) | 2007-09-05 | 2014-11-25 | Novo Nordisk A/S | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use |
US9409966B2 (en) | 2007-09-05 | 2016-08-09 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
JP2012511586A (ja) * | 2008-12-10 | 2012-05-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 医薬組成物 |
JP2013514323A (ja) * | 2009-12-16 | 2013-04-25 | ノヴォ ノルディスク アー/エス | Glp−1アナログ及び誘導体 |
US10960052B2 (en) | 2010-12-16 | 2021-03-30 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
US11382957B2 (en) | 2010-12-16 | 2022-07-12 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
US11034746B2 (en) | 2011-04-12 | 2021-06-15 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
US11117947B2 (en) | 2011-04-12 | 2021-09-14 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
JP2014530892A (ja) * | 2011-10-28 | 2014-11-20 | ファリス バイオテック ゲーエムベーハー | 心臓虚血再灌流障害からの保護のためのポリペプチド |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US11123296B2 (en) | 2012-03-22 | 2021-09-21 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
US11759501B2 (en) | 2012-03-22 | 2023-09-19 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US11759502B2 (en) | 2012-03-22 | 2023-09-19 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US11759503B2 (en) | 2012-03-22 | 2023-09-19 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US11033499B2 (en) | 2012-06-20 | 2021-06-15 | Novo Nordisk A/S | Tablet formulation comprising a GLP-1 peptide and a delivery agent |
US11833248B2 (en) | 2018-02-02 | 2023-12-05 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Also Published As
Publication number | Publication date |
---|---|
EP0512042B1 (en) | 1998-04-08 |
JP2003192698A (ja) | 2003-07-09 |
CA2073856C (en) | 2002-12-03 |
WO1991011457A1 (en) | 1991-08-08 |
CA2073856A1 (en) | 1991-07-25 |
EP0512042A4 (en) | 1993-02-17 |
ATE164852T1 (de) | 1998-04-15 |
JP2004196825A (ja) | 2004-07-15 |
JP2005132848A (ja) | 2005-05-26 |
DE69129226T2 (de) | 1998-07-30 |
EP0512042A1 (en) | 1992-11-11 |
DE69129226D1 (de) | 1998-05-14 |
JP3262329B2 (ja) | 2002-03-04 |
JP2001151798A (ja) | 2001-06-05 |
ES2113879T3 (es) | 1998-05-16 |
DK0512042T3 (da) | 1998-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05506427A (ja) | 糖尿病治療に有用なglp―1アナログ | |
US5545618A (en) | GLP-1 analogs useful for diabetes treatment | |
CN108135981B (zh) | 胰高血糖素受体激动剂 | |
JP4496183B2 (ja) | グルカゴン様ペプチド−2、ならびにその治療への使用 | |
US5834428A (en) | Glucagon-like peptide-2 and its therapeutic use | |
CN104945500B (zh) | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 | |
CN103857408B (zh) | 胰高血糖素/glp‑1受体协同激动剂 | |
EP2084182B1 (en) | Antidiabetic compounds | |
EP2231701B1 (en) | Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities | |
EP0438519B1 (en) | Therapeutic peptides | |
JP2014129382A (ja) | ソマトスタチン受容体2アンタゴニスト | |
KR102700014B1 (ko) | 당뇨병 치료용 펩타이드 | |
JP7553115B2 (ja) | 糖尿病治療のためのペプチド断片 | |
CN109715185A (zh) | 水溶性且化学稳定的胰高血糖素肽 | |
Minnion | Characterisation of Oxyntomodulin and Development of an Oxyntomodulin Analogue for Use in Metabolic Research Studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071221 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081221 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091221 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101221 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101221 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111221 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111221 Year of fee payment: 10 |